

**REMARKS**

Claims 1-52 are currently pending in this application. Claims 8, 26 and 40 have been canceled in this Amendment, without admission and without prejudice to Applicants' right to pursue the subject matter of those canceled claims in either this or other (e.g., continuing or divisional) patent applications. Claims 1, 3-7, 9-18, 20, 21, 23, 24, 27-32, 34-39, 41-47, and 49-51 have been amended, also without prejudice or admission. Specifically, claims 1 and 13 have been rewritten in Markush format. Claims 7, 9, 10, 13, 15, 20, 21, 23, 27, 50, and 51 have been amended to depend from only claim 1. Claims 17, 18, 47, and 49 have been amended to depend only from claim 15. Claim 24 has been amended to depend only from claim 23. Claims 29-32, and 35-36 have been amended to depend only from claim 27. Claim 34 has been amended to depend only from claim 32. Claims 38 and 42 have been amended to depend from claim 1, 15, 18, 19, 20, or 23. Claim 37 has been amended to recite two diseases previously listed within claim 36. Claims 39, 45, and 46 have been amended to depend from claim 1 or 15. Claims 40 and 41 have been amended to depend only from claim 38. Claims 3-7, 9-12, 14-16, 28-30, 32-36, and 43-44, all dependent claims, have been amended to recite, e.g., "*the polypeptide*," "*the functional equivalent*," "*the method*," etc. to emphasize their dependence. Therefore, the above amendments simply amend the dependence of the claims and introduce no new matter.

Claim 41 has been amended to recite "The pharmaceutical composition of claim 38 administered for the treatment of diseases associated with T cells, T cell proliferation, or T cell regulation." Support for this amendment is found directly in claim 41 as filed and introduces no new matter.

Claims 10, 14, 20, and 41 have been amended to recite subject matter in accordance with U.S. practice and form.


Hence, the amendments are fully supported by this application as filed, and do not introduce new matter. Entry and consideration of these amendments are therefore respectfully requested.

**CONCLUSION**

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: September 26, 2005

Respectfully submitted,

By   
Jonathan M. Spenner, Ph.D.

Registration No.: 57,268  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant